Management of FLT-3 mutated AML

RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY.

PIM KINASES INHIBITORS AND PYRIMIDINE-BASED ANTICANCER AGENTS

EXPLORING THE PROTEIN KINASE INHIBITORY ACTIVITY OF QUINAZOLINES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

FLT3 Internal Tandem Duplication Mutation, c MPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients

Quinoxaline Derivatives Anti-Cancer Activities Through Protein Kinases Inhibition: A review

PYRIDINE DERIVATIVES AS ANTICANCER AGENTS: FDA-APPROVED DRUGS AND PROMISING REPORTED COMPOUNDS

Insights into Novel Drugs Targeting Bcl-2 protein as Potential Anti-cancer Agents

FMS-like tyrosine kinase 3 (Internal Tandem Duplication) gene mutation in Acute Myeloid Leukemia patients and its association with CD34

Design, Synthesis, Molecular Docking Studies and in Silico Prediction of ADME Properties of New 5-Nitrobenzimidazole/thiopyrimidine Hybrids as Anti-angiogenic Agents Targeting He